Back to top
more

Immunomedics, Inc. (IMMU)

(Delayed Data from NSDQ)

$14.74 USD

14.74
2,889,678

-0.16 (-1.07%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[IMMU]

Reports for Purchase

Showing records 41 - 60 ( 68 total )

Industry: Medical - Biomedical and Genetics

Record: 41

09/17/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 42

09/12/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 43

09/11/2019

Company Report

Pages: 4

Competitor Antibody-Drug Conjugate Candidate Toxicity Profile Should Alleviate Concern, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 44

09/03/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 45

08/08/2019

Company Report

Pages: 5

Indication Profile Clarified; IMMU-132 Filing on Track; 2Q19 Financials Reported; Reiterate Buy; Lowering PT to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 46

07/23/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 47

06/04/2019

Company Report

Pages: 4

Standing Firm on Sacituzumab Lung Cancer Prospects; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 48

05/13/2019

Company Report

Pages: 5

Delayed Sacituzumab Market Entry Does Not Shake Our Confidence; Reiterate Buy and Lowering PT to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 49

04/30/2019

Company Report

Pages: 5

Recent Weakness Creates Favorable Entry Point Given Lucrative Asian Licensing Deal; Reiterate Buy; Raising Target to $29

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 50

04/24/2019

Company Report

Pages: 5

Balversa Urothelial Carcinoma Profile Bodes Well for Immunomedics; Our KOL Call Expert Opines Positively; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 51

04/02/2019

Company Report

Pages: 3

Our Forecasts Take Sacituzumab Competition Into Account; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 52

03/04/2019

Company Report

Pages: 34

Shifting the Paradigm in Breast Cancer, and Much More; Initiating at Buy and $28 Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 53

11/06/2018

Company Report

Pages: 8

Very busy second half - Q2 results and clinical trial progress

Provider: Edison Investment Research Limited

Price: .00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 54

05/14/2013

Company Report

Pages: 4

Dropping Coverage

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 55

09/10/2012

Industry Report

Pages: 44

September 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 56

08/27/2012

Company Report

Pages: 5

Downgrading to NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 57

05/09/2012

Company Report

Pages: 6

FQ3:12 - Next Up, ASCO Kicks off Data-Filled June - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 58

02/09/2012

Company Report

Pages: 6

Quarterly Update - 90Y-clivatuzumab With Low-Dose Gemcitabine May Enhance Market Position in Pancreatic Cancer

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 59

01/18/2012

Daily Note

Pages: 5

ASCO-GI Data Preview: 90Y-Clivatuzumab Plus Gemcitabine Tolerability Data Anticipated

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 60

12/29/2011

Company Report

Pages: 9

Gets $30M and Oncology Right in Updated Epratuzumab Agreement

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party
// eof